File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: Subgroup analysis from celecoxib antiaromatase neoadjuvant trial

TitleHer2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: Subgroup analysis from celecoxib antiaromatase neoadjuvant trial
Authors
Issue Date2004
PublisherAmerican Association for Cancer Research.
Citation
Clinical Cancer Research, 2004, v. 10 n. 14, p. 4639-4644 How to Cite?
AbstractPurpose: Many studies suggest that Her2/neu play an important role in neoadjuvant endocrine therapy. This study aimed to determine whether the level of Her2/neu expression in advanced breast cancer changes after antiaromatase neoadjuvant treatment, as well as to identify the relationship between Her2/neu expression and response to this kind of therapy. Experimental Design: Thirty-six postmenopausal patients with hormonal receptor-positive primary breast cancer were included in a study of three monthly cycles of neoadjuvant endocrine therapy with either Aromasin (25 mg daily) or Femara (2.5 mg daily). Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) for Her2/neu were conducted both on pretreatment biopsies and surgical tumors. Results: Using IHC, 5 of 36 (13.9%) of the patients had a Her2/neu overexpression after treatment, as compared with 16 of 36 (44.4%) before. Meanwhile, there was no change in 21 (58,3%) patients, and through FISH, there was a change from amplification to no amplification in 15 (41.7%) patients. The response rate to the treatment was 75% for Her2/neu (+) tumors and 35% for Her2/neu (-) tumors (P = 0.017) while FISH was performed. The response rate was also significantly affected by the decrease in Her2/neu states after the treatment, with 73% of the tumors showing decreased Her2/neu espression and with 38% of the tumors showing no change of Her2/neu expression (P = 0.037). Conclusions: Using both IHC and FISH, advanced breast cancers show statistical evidence of decreasing incidence of Her2/neu expression after antiaromatase neoadjuvant treatment. Our data also suggest that Her2/neu expression and its change during the treatment might be predictive markers for this kind of therapy.
Persistent Identifierhttp://hdl.handle.net/10722/71884
ISSN
2015 Impact Factor: 8.738
2015 SCImago Journal Rankings: 5.314
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorZhu, Len_HK
dc.contributor.authorChow, LWCen_HK
dc.contributor.authorLoo, WTYen_HK
dc.contributor.authorGuan, XYen_HK
dc.contributor.authorToi, Men_HK
dc.date.accessioned2010-09-06T06:36:06Z-
dc.date.available2010-09-06T06:36:06Z-
dc.date.issued2004en_HK
dc.identifier.citationClinical Cancer Research, 2004, v. 10 n. 14, p. 4639-4644en_HK
dc.identifier.issn1078-0432en_HK
dc.identifier.urihttp://hdl.handle.net/10722/71884-
dc.description.abstractPurpose: Many studies suggest that Her2/neu play an important role in neoadjuvant endocrine therapy. This study aimed to determine whether the level of Her2/neu expression in advanced breast cancer changes after antiaromatase neoadjuvant treatment, as well as to identify the relationship between Her2/neu expression and response to this kind of therapy. Experimental Design: Thirty-six postmenopausal patients with hormonal receptor-positive primary breast cancer were included in a study of three monthly cycles of neoadjuvant endocrine therapy with either Aromasin (25 mg daily) or Femara (2.5 mg daily). Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) for Her2/neu were conducted both on pretreatment biopsies and surgical tumors. Results: Using IHC, 5 of 36 (13.9%) of the patients had a Her2/neu overexpression after treatment, as compared with 16 of 36 (44.4%) before. Meanwhile, there was no change in 21 (58,3%) patients, and through FISH, there was a change from amplification to no amplification in 15 (41.7%) patients. The response rate to the treatment was 75% for Her2/neu (+) tumors and 35% for Her2/neu (-) tumors (P = 0.017) while FISH was performed. The response rate was also significantly affected by the decrease in Her2/neu states after the treatment, with 73% of the tumors showing decreased Her2/neu espression and with 38% of the tumors showing no change of Her2/neu expression (P = 0.037). Conclusions: Using both IHC and FISH, advanced breast cancers show statistical evidence of decreasing incidence of Her2/neu expression after antiaromatase neoadjuvant treatment. Our data also suggest that Her2/neu expression and its change during the treatment might be predictive markers for this kind of therapy.en_HK
dc.languageengen_HK
dc.publisherAmerican Association for Cancer Research.en_HK
dc.relation.ispartofClinical Cancer Researchen_HK
dc.subject.meshAgeden_HK
dc.subject.meshAged, 80 and overen_HK
dc.subject.meshAndrostadienes - therapeutic useen_HK
dc.subject.meshAntineoplastic Agents - therapeutic useen_HK
dc.subject.meshAromatase Inhibitors - therapeutic useen_HK
dc.subject.meshBreast Neoplasms - genetics - metabolism - therapyen_HK
dc.subject.meshCyclooxygenase Inhibitors - therapeutic useen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshGene Expression Regulation, Neoplasticen_HK
dc.subject.meshHumansen_HK
dc.subject.meshImmunohistochemistryen_HK
dc.subject.meshIn Situ Hybridization, Fluorescenceen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshNeoadjuvant Therapyen_HK
dc.subject.meshNitriles - therapeutic useen_HK
dc.subject.meshPrognosisen_HK
dc.subject.meshPyrazoles - therapeutic useen_HK
dc.subject.meshReceptor, erbB-2 - analysis - geneticsen_HK
dc.subject.meshSulfonamides - therapeutic useen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.subject.meshTriazoles - therapeutic useen_HK
dc.titleHer2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: Subgroup analysis from celecoxib antiaromatase neoadjuvant trialen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1078-0432&volume=10&issue=14&spage=4639&epage=4644&date=2004&atitle=Her2/neu+expression+predicts+the+response+to+antiaromatase+neoadjuvant+therapy+in+primary+breast+cancer:+subgroup+analysis+from+celecoxib+antiaromatase+neoadjuvant+trialen_HK
dc.identifier.emailGuan, XY:xyguan@hkucc.hku.hken_HK
dc.identifier.authorityGuan, XY=rp00454en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1158/1078-0432.CCR-04-0057en_HK
dc.identifier.pmid15269135-
dc.identifier.scopuseid_2-s2.0-3242712110en_HK
dc.identifier.hkuros100394en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-3242712110&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume10en_HK
dc.identifier.issue14en_HK
dc.identifier.spage4639en_HK
dc.identifier.epage4644en_HK
dc.identifier.isiWOS:000222840700006-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridZhu, L=7404202051en_HK
dc.identifier.scopusauthoridChow, LWC=7202532995en_HK
dc.identifier.scopusauthoridLoo, WTY=7003567474en_HK
dc.identifier.scopusauthoridGuan, XY=7201463221en_HK
dc.identifier.scopusauthoridToi, M=7103161459en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats